Systemic lupus erythematosus (SLE) can be diagnosed by affixing a plurality of light sources and a plurality of light detectors against the subject's body near a joint, and sequentially transmitting light from each of the plurality of light sources into the subject's body. Signals are acquired from each of the plurality of light detectors. The rise time of the acquired signals that occurs in response to an inflation of a pressure cuff is determined, and an indication of whether the joint is affected by SLE is made based on the determined rise time. In some embodiments, a plateau time of the acquired signals is also acquired, and the indication of whether the joint is affected by SLE is made based on the determined rise time and the determined plateau time.

It is provided a device for non-invasively and continuously extracting interstitial fluid comprising or not comprising an immunogenic compound from the skin of a subject comprising an electroporator generating a non-pulsed voltage coupled to a pulsed voltage between at least one moving electrode and an electrical conducting adhesive for non-heating irreversibly electroporating the skin; a vacuum pump providing a negative pressure above the skin; and a collecting chamber for collecting the interstitial fluid extracted from the skin wherein the device can be used for detecting Covid-19 and/or extracting an antibody produced in the subject.

The present invention relates to a metabolic biomarker set for use in assessing breast cancer in a mammalian subject. In particular, the invention relates to a metabolic biomarker set for screening and/or diagnosing breast cancer, the metabolic biomarker set comprising at least (a) one amino acid selected from glutamine, glutamate and serine, and one lipid, or (b) glutamine and glutamate. Further, the invention relates to a metabolic biomarker set for prediction of therapeutic response to breast cancer neoadjuvant chemotherapy. Further, the invention relates to a metabolic biomarker set for assessing biochemical reflection of breast cancer tumor activity. Further, the invention relates to a metabolic biomarker set for subclassification between intrinsic breast cancer tumor subtypes. Moreover, the present invention relates to a method for assessing breast cancer, which comprises obtaining a biological sample, preferably blood, from a mammalian subject and measuring in the biological sample the amount and/or ratios of metabolites. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess breast cancer.

Systems and methods are disclosed that facilitate providing guidance to a user during performance of a program or routine using a personalized avatar. In an aspect, a system includes a reception component configured to receive biochemical information about a physiological state or condition of a user, including information identifying a presence or a status of one or more biomarkers. The system further includes an analysis component configured to determine or infer one or more characteristics of the physiological state or condition of the user based on the information identifying the presence or the status of the one or more biomarkers, and a visualization component configured to adapt an appearance of an avatar presented to the user based on the one or more characteristics to reflect the one or more characteristics.

Embodiments of the present disclosure relate to methods, apparatus, and computer readable medium for detecting an immune factor responsive to a contrast agent. In some embodiments, pre-contrast image data, early timepoint image data, and delayed timepoint image data are received. In some embodiments, an early timepoint map is generated using a comparison of the pre-contrast image data to the early timepoint image data, and a delayed timepoint map is generated using a comparison of the pre-contrast image data to the delayed timepoint image data, where the early timepoint map represents intravascular contrast, the delayed timepoint map represents the intravascular contrast and extravascular contrast, and the extravascular contrast indicates the immune factor. In some embodiments, a combined immune factor map is generated by voxel-wise subtraction of the early timepoint map from the delayed timepoint map.

Data analysis is combined with physiological data to provide indications of the health of bodily systems both acute and chronic time frames. The results can confirm the uniqueness of bio-metric security. It can also enhance both sport safety, rehab and fitness goals. The compared change(s) pattern can help for remote/self health monitor as well as wellness tracking.

A system is provided to provide triage recommendations for animals. The system accesses a syndrome mapping of syndromes to complaints, each syndrome having a triage category. The system accesses a complaint mapping of complaints to symptoms. Each symptom for a complaint has a weight. The system receives indications of a current complaint and current symptoms of an animal. Each current symptom has a score. The system identifies the triage category based on a syndrome to which the current complaint and the current symptoms apply, factoring in the weights and the scores. The system provides a recommendation for the animal based on the identified triage category.

A system is provided to provide triage recommendations for animals. The system accesses a syndrome mapping of syndromes to complaints, each syndrome having a triage category. The system accesses a complaint mapping of complaints to symptoms. Each symptom for a complaint has a weight. The system receives indications of a current complaint and current symptoms of an animal. Each current symptom has a score. The system identifies the triage category based on a syndrome to which the current complaint and the current symptoms apply, factoring in the weights and the scores. The system provides a recommendation for the animal based on the identified triage category.

A system is provided to provide triage recommendations for animals. The system accesses a syndrome mapping of syndromes to complaints, each syndrome having a triage category. The system accesses a complaint mapping of complaints to symptoms. Each symptom for a complaint has a weight. The system receives indications of a current complaint and current symptoms of an animal. Each current symptom has a score. The system identifies the triage category based on a syndrome to which the current complaint and the current symptoms apply, factoring in the weights and the scores. The system provides a recommendation for the animal based on the identified triage category.

Described herein are membrane permeabilizing peptides and antimicrobial peptides, polynucleotides encoding the peptides, and compositions containing the peptides. Furthermore, described herein are methods for using the peptides, polynucleotides, and compositions for research, diagnosis, and therapy.